tbuckley/cabot-search huggingface dataset:
Double jeopardy: Minority stress and the influence of transgender identity and race/ethnicity
Authors: Krystina Millar, Caroline V. Brooks
Journal: International Journal of Transgender Health (2021)

Background: Prior research suggests transgender individuals with multiple minority statuses experience higher psychological stress compared to their singly disadvantaged counterparts, and both Black, Indigenous, People of Color (BIPOC), and transgender minorities experience more frequent and severe forms of discrimination than White and cisgender individuals. Aims: This study aims to examine racial/ethnic differences in gender-related discrimination and psychological distress within a sample of transgender individuals. Methods: Using data from a convenience sample of 99 self-identified transgender adults recruited through North American LGBTQ organizations, data were analyzed to determine the relationship between race/ethnicity, gender minority stress, and psychological distress. Results: When White and BIPOC participants are compared, no significant group differences were found in levels of gender discrimination or victimization. However, some individual racial/ethnic groups reported significantly higher or lower scores and results indicate that changes in reported gender minority stress are in fact positively correlated with reported psychological distress. Conclusion: This research highlights that BIPOC are a heterogeneous group; by solely examining race/ethnicity as a binary variable, studies mask potential important differences among different groups.
Incidence and Impact of Activating Mutations of the RAS-RAF-MEK-ERK Pathway in Patients with Philadelphia-Negative (Ph-negative) Myeloproliferative Neoplasms (MPNs) and Myelodysplastic/Myeloproliferative Disorders–Unclassified (MDS/MPD-U)
Authors: Fabio PS Santos, Bianca Lisboa, Tarcila S Datoguia, Ricardo Helman, Welbert Oliveira Pereira, Renato D Puga, Mariana Miyagi, Evelyn HA da Mata, Rodrigo Santucci, Guilherme F Perini, Eizabeth Xisto Souto, Carolina Kassab, Leandro Padua, Patricia W Bollman, Marcia Higashi, Rodolfo Soares, Adriana Valente Fadel, Juliane Musacchio, Ana Fernandes Schriefer, Marco Aurelio Salvino, Danielle Leao Cordeiro De Farias, Leila Martins Perobelli, Erika MM Costa, Marinus M Lima, Vinicius R. P. Mattos, Paulo A. A. Silveira, Nydia Bacal, Joao Carlos Guerra, Alanna Mara P. S Bezerra, Denise da Cunha Pasqualin, Isabel C Bello, Michelli Silva Diniz, Sandra S Nakashima, Elvira Velloso, Nelson Hamerschlak, Paulo Vidal Campregher
Journal: Blood (2014)
Adult “Triple Negative” ACUTE Lymphoblastic Leukemia Genome Wide Characterization
Authors: Anna Ferrari, Valentina Robustelli, Eugenio Fonzi, Andrea Ghelli Luserna Di Rora, Marco Manfrini, Cristina Papayannidis, Stefania Paolini, Italo Valle, Vincenza Solli, Antonella Padella, Giorgia Simonetti, Giulia Ferrari, Margherita Perricone, Enrica Imbrogno, Sarah Parisi, Mariachiara Abbenante, Giovanni Marconi, Chiara Sartor, Nicoletta Testoni, Daniel Remondini, Michele Cavo, Giovanni Martinelli
Journal: Blood (2017)
P1.14-42 Apatinib Combined with EGFR - TKI in Treating Advanced Non-Small Cell Lung Cancer with EGFR - TKI Resistance (Data Updated)
Authors: R. Tian, X. Song, Y. Guo, X. Zhang, W. Guo, H. Zhu, F. Shen, J. Xu, X. Zhang, R. Wang, X. Ren, J. Li
Journal: Journal of Thoracic Oncology (2019)
P1.09-24 Tumor Necrosis Correlates with PD-L1 and PD-1 Expression in Lung Adenocarcinoma
Authors: J. Moldvay, V. Téglási, O. Pipek, L. Rojkó, T. Glasz, A. Vágvölgyi, I. Kovalszky, M. Gyulai, Z. Lohinai, E. Rásó, J. Tímár, B. Döme, Z. Szállási, L. Reiniger
Journal: Journal of Thoracic Oncology (2019)
MA02.01 Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial)
Authors: B. Massuti, J.M. Sanchez, M. Cobo, T. Moran, J.L. Gonzalez Larriba, I. Barneto, J. De Castro Carpeno, L. Iglesias, M.A. Muñoz, G. López-Vivanco, D. Isla, R. López, R. De Las Penas, D. Rodriguez-Abreu, A. Artal, E. Esteban, M. Provencio, E. Pereira, J. Sanchez-Payá, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
Taking antihypertensives at bedtime nearly halves cardiovascular deaths when compared with morning dosing, study finds
Authors: Susan Mayor
Journal: BMJ (2019)

Taking antihypertensive medicine at bedtime is associated with improved blood pressure control and a near halving of cardiovascular deaths and events when compared with morning dosing, a study of nearly 20 000 hypertensive patients in primary care has shown.1

“Current guidelines on the treatment of hypertension do not mention or recommend any preferred treatment time,” said Ramon Hermida, lead author of the study and director of the bioengineering and chronobiology labs at the University of Vigo in Spain. “Morning ingestion has been the most common recommendation by physicians based on the misleading goal of reducing morning blood pressure levels.”

But he noted, “The results of this study show that patients who routinely take their antihypertensive medication at bedtime, as opposed to when they wake up, have better controlled blood pressure and, most importantly, a …
P1.04-22 Potential DNA Repair Biomarker for Response to Immunotherapy of Lung Cancer Patients
Authors: Z. Livneh, T. Paz-Elizur, Y. Leitner-Dagan, K. Meyer, B. Barak Markus, F. Giorgi, M. O’Reilly, H. Kim, Y. Evgy, R.C. Rintoul, B. Ponder
Journal: Journal of Thoracic Oncology (2019)
MA25.07 Genomic Profiling of Lung Adenocarcinoma by Targeted NGS Using Extracellular Vesicle-Derived DNA in Bronchoalveolar Lavage Fluid
Authors: S. Lee, K.Y. Lee, J.Y. Hur, H. Kim, W.S. Kim, I.A. Kim, H.Y. Park
Journal: Journal of Thoracic Oncology (2019)
Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides
Authors: John T. O'Malley, Adele de Masson, Elizabeth L. Lowry, Anita Giobbie-Hurder, Nicole R. LeBoeuf, Cecilia Larocca, Ahmed Gehad, Edward Seger, Jessica E. Teague, David C. Fisher, Thomas S. Kupper, Phillip M. Devlin, Rachael A. Clark
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Mycosis fungoides is the most common subtype of cutaneous T-cell lymphoma. Skin-directed treatments often improve but do not cure mycosis fungoides skin lesions. The purpose of this study was to (i) assess whether remission was associated with malignant T-cell clone depletion at treated sites using either low-dose radiotherapy (LDRT, 8 Gy) or topical steroids and (ii) assess whether a clone-ablative therapy, like LDRT, is associated with overall survival in patients with high-risk early-stage CTCL. Experimental Design: Pre- and posttreatment biopsies from 20 lesional skin samples of 18 patients with mycosis fungoides who received either 8 Gy LDRT (n = 16) or topical steroids (n = 4) underwent high-throughput T-cell receptor sequencing of the TCRB gene to quantify the malignant T-cell clone. For the retrospective chart review, overall survival of 47 high-risk early-stage patients was compared between patients who did or did not receive radiation. Results: LDRT eradicated the clone in 5 of 16 lesions and reduced it &amp;gt;90% in 11 of 16; there were no recurrences in these lesions. Patients treated with topical steroids appeared to clinically improve, but the malignant clone persisted. We found that the number of residual malignant T cells predicted lesion recurrence. A retrospective review showed that early-stage high-risk patients who received radiation as part of their treatment regimen had prolonged overall survival compared with patients who did not. Conclusions: These findings demonstrate that LDRT can eradicate malignant T cells in mycosis fungoides, provides robust disease control, and is associated with improved survival in high-risk early-stage patients.
P1.06-01 Combining Immunoprofile, Immunogenic Collagen and Mismatch Repair Proteins Predicts Risk of Death and Target Therapy in Malignant Mesothelioma
Authors: J. Machado-Rugolo, M. Balancin, V. Martins, J. Miranda, A. Assato, N. Souza, A.P. Velosa, R. Falzoni, A. Ab'saber, W. Teodoro, V. Capelozzi
Journal: Journal of Thoracic Oncology (2019)
Emerging agents and regimens for hepatocellular carcinoma
Authors: Xiao-Dong Zhu, Hui-Chuan Sun
Journal: Journal of Hematology & Oncology (2019)

Abstract Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer mortality globally. Most patients need at least one systemic therapy at different phases of their treatment for HCC. Sorafenib was the first agent shown to improve the survival of patients with advanced HCC. A decade after the approval of sorafenib, most agents failed to improve patient survival more than sorafenib. In recent years, treatment practices have changed, with lenvatinib as another first-line treatment choice and regorafenib, ramucirumab, and cabozantinib as second-line treatment options. Anti-PD-1 antibodies, including nivolumab, pembrolizumab, and camrelizumab, have demonstrated promising anti-tumor effects as monotherapy for advanced HCC in phase II clinical trials. The combination of an anti-PD-1 antibody and an anti-angiogenesis agent has shown more potent anti-tumor effects in early phase clinical trials and is now the hotspot in clinical studies. Furthermore, these agents are investigated in combination treatment with surgery or other loco-regional therapies in patients with early or intermediate-stage HCC.
Conversion to laparoscopy in gastric endoscopic full-thickness resection: adverse event or routine step-up approach?
Authors: Antonino Granata, Alberto Martino, Michele Amata, Davide Cintorino, Duilio Pagano, Dario Ligresti, Mario Traina
Journal: Endoscopy (2019)

A 25-year-old woman was referred to our institute for evaluation of an incidental gastric submucosal tumor (SMT) located in the anterior wall of the antrum, proximal to the incisura angularis ([Fig. 1]). Endoscopic ultrasound (EUS) showed an inhomogeneous hypoechoic lesion with regular margins arising from the muscularis propria ([Fig. 2]). EUS-guided fine-needle biopsy with a 20-gauge needle (EchoTip ProCore, Cook Medical, Limerick, Ireland) was performed. Cytohystological examination was inconclusive. The patient refused long-term endoscopic surveillance. Therefore, after multidisciplinary evaluation, it was decided to perform free-hand endoscopic full-thickness resection (EFTR) with gastric defect closure using the OverStitch suturing device (Apollo Endosurgery, Austin, Texas, USA) ([Video 1]).
P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
Authors: J. Heymach, J. Taube, T. Mitsudomi, D. Harpole, M. Aperghis, L. Trani, M. Powell, P. Dennis, M. Reck
Journal: Journal of Thoracic Oncology (2019)
P2.05-10 Liquid Biopsy: Association Between the Burden of Disease in Patients with EGFR-Mutated NSCLC and the Frequency of Its Detection in Blood
Authors: M. Provencio, F. Franco, A. Sanchez-Hernandez, E. Sánchez Romero, C. Garcia Giron, M. Domine, E. Jantus, M. Barquín Del Romo, J.M. Sánchez, J. Oramas, A.L. Ortega, L.E. Chara, M.a. Sala, B. Hernandez, M. Sereno, V. Calvo De Juan, J. Coves, J. Bosch-Barrera, A. Padilla, J. Balsalobre, R. Blanco, X. Mielgo Rubio, M. Sotelo, A. Romero
Journal: Journal of Thoracic Oncology (2019)
P2.14-17 Correlation Between Clinic-Pathological Data and T790M Detection in EGFR Mutated NSCLC Patients Progressing on 1st/2nd Generation TKIs
Authors: D. Pignataro, M. Tagliamento, M.L. Reale, F. Tabbò, M. Bungaro, C. Paratore, V. Cetoretta, M. De Filippis, V. Bertaglia, F. Passiglia, L. Righi, P. Bironzo, S. Novello
Journal: Journal of Thoracic Oncology (2019)
The Impact of Medicaid Expansion on Diabetes Management
Authors: Jusung Lee, Timothy Callaghan, Marcia Ory, Hongwei Zhao, Jane N. Bolin
Journal: Diabetes Care (2019)

OBJECTIVE Diabetes is a chronic health condition contributing to a substantial burden of disease. According to the Robert Wood Johnson Foundation, 10.9 million people were newly insured by Medicaid between 2013 and 2016. Considering this coverage expansion, the Affordable Care Act (ACA) could significantly affect people with diabetes in their management of the disease. This study evaluates the impact of the Medicaid expansion under the ACA on diabetes management. RESEARCH DESIGN AND METHODS This study includes 22,335 individuals with diagnosed diabetes from the 2011 to 2016 Behavioral Risk Factor Surveillance System. It uses a difference-in-differences approach to evaluate the impact of the Medicaid expansion on self-reported access to health care, self-reported diabetes management, and self-reported health status. Additionally, it performs a triple-differences analysis to compare the impact between Medicaid expansion and nonexpansion states considering diabetes rates of the states. RESULTS Significant improvements in Medicaid expansion states as compared with non–Medicaid expansion states were evident in self-reported access to health care (0.09 score; P = 0.023), diabetes management (1.91 score; P = 0.001), and health status (0.10 score; P = 0.026). Among states with large populations with diabetes, states that expanded Medicaid reported substantial improvements in these areas in comparison with those that did not expand. CONCLUSIONS The Medicaid expansion has significant positive effects on self-reported diabetes management. While states with large diabetes populations that expanded Medicaid have experienced substantial improvements in self-reported diabetes management, non–Medicaid expansion states with high diabetes rates may be facing health inequalities. The findings provide policy implications for the diabetes care community and policy makers.
P2.12-08 Surprisingly Promising Tumor Control Rate of S1 Combination with Anlotinib with Refractory Relapsed SCLC Who Failed ≥ 2 Lines Chemotherapy
Authors: H. Yang, W. Wang, D. Lv, Y. Meng, S. Zhou, X. Wu, F. Kong
Journal: Journal of Thoracic Oncology (2019)
P2.04-44 Combined Immune Checkpoint Blockade in Mesothelioma: In Vivo Investigation of in Vitro Data
Authors: E. Marcq, J. Van Audenaerde, J. De Waele, J. Jacobs, J. Van Loenhout, P. Pauwels, E. Smits, J. Van Meerbeeck
Journal: Journal of Thoracic Oncology (2019)
P1.18-04 Neoadjuvant Ceritinib for Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: SAKULA Trial
Authors: Y. Zenke, K. Yoh, J. Sakakibara-Konishi, H. Daga, Y. Hosomi, N. Nogami, I. Okamoto, S. Matsumoto, S. Kuroda, M. Wakabayashi, S. Nomura, G. Ishii, A. Sato, M. Tsuboi, K. Goto
Journal: Journal of Thoracic Oncology (2019)
EP1.01-62 The Safety Profile and Preliminary Efficacy of Ceritinib 450mg with Food in Chinese ALK/ROS-1 Positive NSCLC Patients
Authors: Y. Tian, P. Yu, X. Yin, K. Wang, M. Huang, Y. Wang, Y. Gong, J. Li
Journal: Journal of Thoracic Oncology (2019)
P2.04-87 Efficacy of Immune Checkpoint Inhibitors for Locally Advanced Non-Small Cell Lung Cancer Patients Before Durvalumab Approval
Authors: T. Fukui, S. Hosotani, I. Soda, H. Ishiyama, M. Ishihara, M. Kasajima, Y. Hiyoshi, S. Igawa, S. Katagiri, K. Naoki
Journal: Journal of Thoracic Oncology (2019)
Slowing ribosome velocity restores folding and function of mutant CFTR
Authors: Kathryn E. Oliver, Robert Rauscher, Marjolein Mijnders, Wei Wang, Matthew J. Wolpert, Jessica Maya, Carleen M. Sabusap, Robert A. Kesterson, Kevin L. Kirk, Andras Rab, Ineke Braakman, Jeong S. Hong, John L. Hartman, Zoya Ignatova, Eric J. Sorscher
Journal: Journal of Clinical Investigation (2019)

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR), with approximately 90% of patients harboring at least one copy of the disease-associated variant F508del. We utilized a yeast phenomic system to identify genetic modifiers of F508del-CFTR biogenesis, from which ribosomal protein L12 (RPL12/uL11) emerged as a molecular target. In the present study, we investigated mechanism(s) by which suppression of RPL12 rescues F508del protein synthesis and activity. Using ribosome profiling, we found that rates of translation initiation and elongation were markedly slowed by RPL12 silencing. However, proteolytic stability and patch-clamp assays revealed RPL12 depletion significantly increased F508del-CFTR steady-state expression, interdomain assembly, and baseline open-channel probability. We next evaluated whether Rpl12-corrected F508del-CFTR could be further enhanced with concomitant pharmacologic repair (e.g., using clinically approved modulators lumacaftor and tezacaftor) and demonstrated additivity of these treatments. Rpl12 knockdown also partially restored maturation of specific CFTR variants in addition to F508del, and WT Cftr biogenesis was enhanced in the pancreas, colon, and ileum of Rpl12 haplosufficient mice. Modulation of ribosome velocity therefore represents a robust method for understanding both CF pathogenesis and therapeutic response.
Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release
Authors: Marjan Abri Aghdam, Roya Bagheri, Jafar Mosafer, Behzad Baradaran, Mahmoud Hashemzaei, Amir Baghbanzadeh, Miguel de la Guardia, Ahad Mokhtarzadeh
Journal: Journal of Controlled Release (2019)
MA15.01 Cellular Prion Protein Transcriptionally Regulated by NFIL3 Enhances Lung Cancer Cell Lamellipodium Formation and Migration
Authors: S. Lin, C. Lin, N. Shih, H. Liu, W. Wang, K. Lin, Y. Lin, Y. Yeh, H. Minato, T. Fujii, Y. Wu, M. Chen, T. Chou
Journal: Journal of Thoracic Oncology (2019)
P1.01-47 Prospective Study for Usefulness of Plasma DNA on Prediction of Third Generation EGFR Tyrosine Kinase Inhibitors (S-PLAT Study)
Authors: C. Nakashima, H. Yoshida, N. Matsumoto, K. Iwanaga, N. Ebi, A. Nishiyama, K. Yatera, S. Kuyama, M. Fukuda, S. Ushijima, H. Umeguchi, D. Harada, K. Kashiwabara, T. Suetsugu, N. Fujimoto, F. Tanaka, H. Uramoto, C. Yoshii, K. Nakatomi, K. Nosaki, Y. Ichikawa, K. Aoe, K. Inoue, K. Takayama, M. Kato, N. Sueoka-Aragane
Journal: Journal of Thoracic Oncology (2019)
P1.06-18 MicroRNA Expression Is Linked to Response of Malignant Pleural Mesothelioma to Cisplatin-Pemetrexed Chemotherapy
Authors: Y. Zhang, V. Orlowski, B. Vrugt, M. Friess, W. Weder, I. Opitz, M. Kirschner
Journal: Journal of Thoracic Oncology (2019)
P1.04-77 Efficacy of Anti-PD-1/L1 Therapy for Advanced Non-Small Cell Lung Cancer with Preexisting Autoimmune Markers
Authors: T. Inoue, M. Kimura, K. Kunimasa, M. Tamiya, H. Kuhara, K. Nishino, T. Hino, T. Kumagai
Journal: Journal of Thoracic Oncology (2019)
Efficacy and Safety of a New Intravenous Immunoglobulin in Adult Subjects with Chronic Idiopathic Thrombocytopenic Purpura.
Authors: Heinz Leibl, Gyula Varga, Zuzana Volkova, Zoltan Gasztonyi, Antonin Hlusi, Jiri Mayer, Krzysztof Chojnowski, Hans-Heinrich Wolf, Marlies Sharkhawy, Borislava G. Pavlova, Karl Birthistle, Werner Engl, Simone Walter, Hartmut J. Ehrlich
Journal: Blood (2005)
P2.01-55 Immunotherapy First or After Nintedanib?: A Spanish Experience
Authors: P. Cruz, L. Gutiérrez Sainz, C. Aguado, M. Antoñanzas, X. Mielgo, L. Cabezón, L.E. Chara, I. Gomez-Barreda, E. Martinez Moreno, Y. Lage Alfranca, A. Velastegui, M. Sotelo, A. Garcia Rueda, M.E. Olmedo, S. Martínez Recio, J. De Castro Carpeno
Journal: Journal of Thoracic Oncology (2019)
P1.18-22 Impact of Using Volumetric Modulated Arc Therapy on Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer
Authors: N. Imano, T. Kimura, T. Kameoka, M. Ochi, Y. Takeuchi, I. Takahashi, I. Nishibuchi, Y. Murakami, D. Kawahara, K. Miki, A. Saito, N. Yasushi
Journal: Journal of Thoracic Oncology (2019)
P2.16-18 Opioid-Induced Constipation in Patients with Cancer Pain in Japan (OIC-J study): A Post-Hoc Analysis of Lung Cancer Patients
Authors: H. Imai, T. Harada, S. Fumita, T. Noriyuki, M. Gamoh, Y. Akashi, M. Okamoto, Y. Kizawa, A. Tokoro
Journal: Journal of Thoracic Oncology (2019)
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy
Authors: Kristin C. Hicks, Karin M. Knudson, Karin L. Lee, Duane H. Hamilton, James W. Hodge, William D. Figg, Peter Ordentlich, Frank R. Jones, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, Sofia R. Gameiro
Journal: Clinical Cancer Research (2019)

Immunotherapy has demonstrated clinical efficacy in subsets of patients with solid carcinomas. Multimodal therapies using agents that can affect different arms of the immune system and/or tumor microenvironment (TME) might increase clinical responses.We demonstrate that entinostat, a class I histone deacetylase inhibitor, enhances the antitumor efficacy of the IL15 superagonist N-803 plus vaccine in 4T1 triple-negative breast and MC38-CEA colon murine carcinoma models. A comprehensive immune and gene-expression analysis was performed in the periphery and/or TME of MC38-CEA tumor-bearing mice.Although N-803 plus vaccine induced peripheral CD8+ T-cell activation and cytokine production, there was no reduction in tumor burden and poor tumor infiltration of CD8+ T cells with minimal levels of granzyme B. For the first time, we demonstrate that the addition of entinostat to N-803 plus vaccine promoted significant tumor control, correlating with increased expression of genes associated with tumor inflammation, enhanced infiltration of activated CD8+ T cells with maximal granzyme B, T-cell responses to multiple tumor-associated antigens, increased serum IFNγ, reduction of regulatory T cells in the TME, and decreased expression of the checkpoint V-domain Ig suppressor of T-cell activation (VISTA) on multiple immune subsets.Collectively, these data demonstrate that the synergistic combination of entinostat, N-803, and vaccine elicits potent antitumor activity by generating a more inflamed TME. These findings thus form the rationale for the use of this combination of agents for patients harboring poorly or noninflamed solid carcinomas.
EP1.01-65 The Relationship Between Preliminary Efficacy and Prognosis After First-Line EGFR-TKI Treatment of Advanced NSCLC
Authors: D. Chen, T. Chu, Q. Chang, Y. Zhang, L. Xiong, R. Qiao, J. Teng, B. Han, R. Zhong
Journal: Journal of Thoracic Oncology (2019)
P2.14-56 Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of EML4-ALK Lung Cancer
Authors: S. Arai, S. Takeuchi, K. Fukuda, A. Nishiyama, A. Tanimoto, H. Taniguchi, M. Satouchi, S. Nanjo, R. Katayama, M. Nishio, M. Zheng, Y. Wu, S. Yano
Journal: Journal of Thoracic Oncology (2019)
P1.14-11 A Prospective Multicenter Study of Target-Capture Deep Sequencing in Paired Tissue and ctDNA to Guide EGFR-Mutated Lung Cancer Treatment
Authors: S. Lu, X. Ai, J. Zhang, W. Lin, J. Cui, C. Xie, A. Liu, X. Hu, Q. Zhao, C. Rao, Y. Zang, X. Hu, J. Zhang, C. Liu, L. Chang, N. He, R. Chen, X. Xia, X. Yi
Journal: Journal of Thoracic Oncology (2019)
P2.04-09 Immune-Related Adverse Events in Advanced Non-Squamous NSCLC Patients Treated with Upfront Checkpoint Inhibitors Combination
Authors: A. Sultan, K. Thein, S. Swarup, N. Jahan, A. Tun, S. Meda, M. Arevalo, T. Naing, T. Htut, N. D’Cunha, S. Awasthi, S. Rehman, L. Tijani, F. Hardwicke
Journal: Journal of Thoracic Oncology (2019)
JCSE01.27 A Novel Non-Invasive Biomarker Based on Peripheral PD-1+CD8+T Cell Receptor Repertoire Predicts Clinical Outcomes of Immunotherapy in NSCLC
Authors: J. Han, Z. Wang, Y. Wang, J. Li, J. Duan, H. Bai, J. Wang
Journal: Journal of Thoracic Oncology (2019)